Hepatic Arterial Infusion of 5-Fluorouracil for Patients With Liver Metastases From Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter, Retrospective Analysis

详细信息    查看全文

• 作者：Hideyuki Nishiofuku ; ^{hmn@naramed-u.ac.jp} ; Toshihiro Tanaka ; Takeshi Aramaki ; Narikazu Boku ; Yoshitaka Inaba ; Yozo Sato ; Masaki Matsuoka ; Toshio Otsuji ; Yasuaki Arai ; Kimihiko Kichikawa
• 关键词：5-FU ; Alkaline phosphatase ; Prognostic factor ; Third-line chemotherapy
• 刊名：Clinical Colorectal Cancer
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：9
• 期：5
• 页码：305-310
• 全文大小：125 K

文摘

Introduction

This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy.

Patients and Methods

Fifty-five patients who had shown disease progression during the prior standard systemic chemotherapy with oxaliplatin, irinotecan, and 5-FU were enrolled. The treatment was weekly HAIC with 5-FU 1000 mg/m²/5 hours through an indwelling catheter-port system.

Results

No major adverse reaction was observed other than grade 3 leukocytopenia (3.6 % ) and hyperbilirubinemia (1.8 % ). The overall response rate and disease control rate were 18.2 % and 70.9 % , respectively. The median progression-free survival and median overall survival (OS) were 2.8 months, and 6.7 months, respectively. The initial sites of disease progression were liver in 14, other than liver in 27, and both in 6. Multivariate analysis identified Eastern Cooperative Oncology Group (ECOG) performance status (PS) ?1 and number of extrahepatic metastatic sites (NMS) ? as favorable prognostic factors for OS (hazard ratio [HR], 8.277; 95 % CI, 3.60-19.0; P = .000 for ECOG PS; and HR, 2.456; 95 % CI, 1.30-4.61; P = .005 for NMS).

Conclusion

HAIC with 5-FU may be a safe and effective treatment for patients with colorectal liver metastases refractory to standard systemic chemotherapy.